WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025.Prof. Jonathan Javitt, MD, MPH will join Prof. Samuel Wilkinson, MD, of the Yale School of Medicine, and  BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on W ...

Good morning everyone. Hope you're doing well right now. Can anyone name an exact moment their life changed.Anyone. You can raise your hand if you want to. Well, most of the people think that they can.Maybe it was the day they moved to a new country, switched schools, or made a life-changing decision. And for sure, those moments feel big, defining, and important. But what if I told you that the real turning points aren't the ones we really remember.What if the biggest changes in our lives have been happenin ...

[Applause] Hello everyone. My name is Sophia and today I'm going to be talking about something really cool and powerful. How small habits could actually change our life often in ways that you wouldn't expect.Now some people think that to improve ourselves we need to do big dramatic things. Some of us might think that we need to study for hours or two hours daily. Now, the surprising truth is not all huge overwhelming changes could actually make the biggest differences.The small consistent changes that you d ...

[Applause] Who here loves to exercise. Maybe you're a marathon runner, a gym enthusiast, or someone who likes to lift weights regularly. But what if I told you that you might be neglecting to work on the most important part of yourself, your brain.Your brain needs its own form of training. And yet, it's the one body part we often forget to work on. Let's explore why exercising your brain might just be the most important workout you'll ever do.Last year, I worked with pain scientists at Boston Children's Hos ...

[Music] [Music] Massive transformation often follows periods of extreme stress. That is because change becomes necessary. For me, that moment occurred as a teenager.After my first semester of playing college baseball, I found myself in a hospital room diagnosed with the doctors told me was an incurable autoimmune disease. My prognosis was poor and there's a lot of uncertainty around my future. But I innately knew one thing.To get better, I had to change. What I soon found out was all the changes I would go ...

[Música] Muito boa tarde, super poderosos. Que prazer estar aqui com vocês hoje. É uma honra para mim poder falar de um tema no qual eu acredito tanto, que é tão transformador, como ativar os seus superperes.Mas antes disso, eu quero trazer para vocês a história de um superherói, do meu superherói, do meu pai, Senr. Carmo José da Silva, que aos 53 anos de idade decidiu realizar um dos seus maiores sonhos, que era cursar a Universidade de Direito. O meu pai naquela altura passou por algumas dificuldades, mas ...

Good evening everyone. Have you ever thought about how your body will age. Somewhere between the age of 30 and 40, we start losing muscle mass at a rate of about 1% each year.That's normal. It's called sarcopenia. We get slower. We get more limited. and we get vulnerable to diseases.On top of these physical challenges, we also have mental and psychological challenges. Anxiety and depression are on the rise and even our teenagers are now stressed. So, what if there was one habit, one practice that you can ad ...

Core Insights - The PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates long-term benefits of PoNS Therapy for gait deficits in individuals with Multiple Sclerosis (MS) [1][2] - The study results were presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, highlighting the importance of treatment adherence for achieving clinically meaningful improvements [2][3] Study Details - The PoNSTEP study is an open-label, observational, interventional multi-center research study assessing adherence to PoNS Therapy for gait deficits in MS patients [5] - The study involved 43 MS participants and was conducted at six Centers of Excellence across the United States [5] - The primary endpoint is the maintenance of gait improvement from the end of supervised therapy to the end of unsupervised therapy, with secondary endpoints including maintenance of improvement over six months [5] Treatment and Mechanism - PoNS Therapy combines the Portable Neuromodulation Stimulator (PoNS) device with physical therapy, applied for 100-120 minutes per day [5][7] - The PoNS device delivers mild electrical impulses to the tongue and is indicated for short-term treatment of gait deficits due to mild-to-moderate MS symptoms [7][8] Clinical Impact and Recognition - The study provides the first clinical trial evidence of PoNS Therapy's long-term benefits for functional rehabilitation in the MS population [3] - There is growing recognition of PoNS Therapy's direct effect on the central nervous system and its targeted mechanism of action compared to other interventions [3] Reimbursement and Access - Helius Medical Technologies has successfully obtained initial reimbursement from federal and private payers, which is expected to lower barriers to prescribing PoNS Therapy [4] - The company is actively engaging with health insurance providers to expand access to PoNS Therapy for all individuals with MS [3][4]

Core Insights - BetterLife Pharma Inc. is focused on developing BETR-001, a non-hallucinogenic neuroplastogen aimed at treating psychiatric and neurological disorders [1][8] - BETR-001 has shown significant potential in promoting neuroplasticity, which is crucial for brain rewiring and forming new neuronal connections [2][4] - The company has received a composition of matter patent for BETR-001 and is preparing for IND filing and human trials projected for H1 2026 [7][9] Group 1: Scientific Developments - BETR-001 has been demonstrated to significantly induce the formation of new dendrites and spines in cultured rat brain cortical neurons, outperforming ketamine in these aspects [2][3] - The drug's neuroplasticity data suggests its effectiveness in treating various conditions such as depression, anxiety, PTSD, traumatic brain injury, migraines, and neuropathic pain [4][9] Group 2: Regulatory and Development Status - BetterLife has completed most of the required IND-enabling studies and has had a pre-IND meeting with the FDA [7] - The company is also developing BETR-002, which targets anxiety-related disorders, and is exploring strategic alternatives for other drug candidates [10]

Core Insights - Helius Medical Technologies, Inc. will present the final results of the PoNSTEP study, which confirms the efficacy of the Portable Neuromodulation Stimulator (PoNS) device for improving gait in individuals with multiple sclerosis (MS) [1][2] - The study highlights a statistically significant relationship between adherence to PoNS therapy and improvement in gait, indicating that consistent use leads to sustained benefits [3][4] Study Overview - The PoNSTEP study was a three-phase, real-world therapeutic experience designed to evaluate the impact of adherence on gait deficits and long-term outcomes in MS patients [3][8] - Participants underwent two weeks of supervised therapy, followed by 12 weeks of combined clinic and at-home use, concluding with a six-month follow-up to assess the durability of improvements [3][9] Key Findings - Stronger adherence to PoNS therapy resulted in better therapeutic outcomes, with highly adherent participants achieving over 6 points improvement in their Dynamic Gait Index (DGI) scores during the first 14 weeks [4][5] - More than 95% of participants maintained their level of improvement six months post-treatment, demonstrating the durability of the therapy's effects [5][7] Clinical Implications - The study provides evidence of the effectiveness of neuromodulation and neuroplasticity in rehabilitating gait deficits in MS patients, marking a significant advancement in treatment options for this population [7][10] - PoNS therapy is now accessible through insurance via the U.S. Department of Veterans Affairs and Department of Defense, with some commercial healthcare providers beginning to reimburse the device [7][12] About PoNS Device - The Portable Neuromodulation Stimulator (PoNS) is a non-implantable device that delivers neurostimulation through a mouthpiece, used in conjunction with physical rehabilitation exercises to improve balance and gait in MS patients [12][14] - The device is indicated for short-term treatment of gait deficits due to mild-to-moderate MS symptoms and is prescribed for patients aged 22 and older [12][13]